## WST: West Pharmaceutical Services, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.5% below STRENGTH zone (3.0-6.0%); PEG 3.50 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.6% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($260.39)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Reasons to retain West Pharmaceutical stock in your portfolio for now**
- Source: MSN | 20251224T040849 | Bullish | Relevance: 100%
- This article from MSN provides reasons to retain West Pharmaceutical stock. Despite not having direct content, the title suggests a positive outlook on the company's shares. Investors could infer that factors support holding onto this stock in their portfolios.

**2. Swedbank AB Grows Stock Position in IES Holdings, Inc. $IESC**
- Source: MarketBeat | 20251226T110851 | Somewhat-Bullish | Relevance: 63%
- Swedbank AB significantly increased its stake in IES Holdings, Inc. (NASDAQ:IESC) by 153.1% in Q3, now owning 81,000 shares valued at $32.21 million. This comes as company insiders have sold shares totaling about $96.39 million, while institutional investors now own 86.60% of the stock. Analysts have a positive outlook, with Wall Street Zen upgrading IES to a "strong-buy" rating.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $285 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | init | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 2 ($0.14M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.9% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Vanguard Group Inc: 13.5% (+4.2%)
- Blackrock Inc.: 9.0% (-2.3%)
- State Street Corpora: 4.5% (-1.9%)
- Bank Of New York Mel: 4.0% (-9.4%)
- Artisan Partners Lim: 3.9% (+22.2%)

### Key Risks

1. Valuation stretched: PEG 3.5x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.50 signals overvaluation risk, limited margin of safety. Forward P/E 35.2x stretched relative to 10% growth. Quality metrics strong (ROA 10%, margin 16%). Balance sheet: strong liquidity (2.9x), low leverage (D/E 0.35). Institutional flow bearish (7 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $19.7B |
| Beta | 1.17 |
| 52W Range | $187.43 - $348.90 |
| Short Interest | 3.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.50 |
| Forward P/E | 35.2 |
| Current P/E | 38.6 |
| YoY Growth | 9.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 1.1% to -0.5% (-1.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.5pp (needs >3.0% for momentum thesis). MACD histogram positive (0.59), confirming momentum. RSI neutral at 52. OFD pattern: -DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.51% (CS: 61) | Neutral |
| RSI_14 | 51.9 | Neutral |
| MACD Histogram | 0.59 | Bullish |
| vs SMA20 | 1.005x | Above |
| vs SMA50 | 0.998x | Below |
| vs SMA200 | 1.133x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $274.49
- **Stop Loss:** $260.39 (5.1% risk)
- **Target:** $288.59 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 93
- **Position Value:** $25,527.57
- **Portfolio %:** 25.53%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-12 (Est: $1.83)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.71 | $1.96 | +14.5% |
| 2025Q2 | $1.54 | $1.84 | +19.7% |
| 2025Q1 | $1.26 | $1.45 | +15.3% |
| 2024Q4 | $1.73 | $1.82 | +5.3% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*